Evidence map›Paper›PMID 40851492›Full record

ArticleChemMedChem2025

Towards the Use of Metabolic Volatiles in Breath for Determining Drug Response: Gstachamine as an Unlabeled Substrate to Measure CYP3A4 Activity.

Valentina Stock, Rebecca Hofer, Klaus R Liedl, Jakob Troppmair, Thierry Langer, Hubert Gstach, Christian Dank, Sarah Kammerer, Veronika Ruzsanyi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Valentina StockInstitute for Breath Research, University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria.ORCID https://orcid.org/0009-0005-6942-4527
Rebecca HoferInstitute for Breath Research, University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria.ORCID https://orcid.org/0009-0001-8854-1199
Klaus R LiedlDepartment of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-0985-2299
Jakob TroppmairDaniel Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria.
Thierry LangerDepartment of Pharmaceutical Chemistry, University of Vienna, Althanstraße 14, 1090, Vienna, Austria.ORCID https://orcid.org/0000-0002-5242-1240
Hubert GstachDepartment of Pharmaceutical Chemistry, University of Vienna, Althanstraße 14, 1090, Vienna, Austria.
Christian DankDepartment of Pharmaceutical Chemistry, University of Vienna, Althanstraße 14, 1090, Vienna, Austria.ORCID https://orcid.org/0000-0001-7440-4153
Sarah KammererInstitute for Breath Research, University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-9284-2242
Veronika RuzsanyiInstitute for Breath Research, University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria.ORCID https://orcid.org/0000-0001-9631-364X

Funding

Austrian Science Fund (FWF)
6 · The paper itself

Abstract

Breath analysis is a promising noninvasive diagnostic tool, but the clinical applicability of breath tests depends on several factors. A salient criterion pertains to the presence of substrates with the ability to produce detectable volatile metabolites during the metabolism. In this work, we evaluated the potential of two candidate compounds, namely gstachidine and gstachamine, for their use in metabolic breath analysis. Both substrates were evaluated for their toxicity and metabolic conversion in HepG2 cell clones overexpressing CYP3A4. Gstachidine was found to be toxic and did not produce any volatile metabolite. In contrast, gstachamine successfully generated butanone as a volatile metabolite, making it the first substrate to yield a stable VOC detectable exclusively at low ppb

Indexed as

Cytochrome P-450 CYP3AVolatile Organic CompoundsBreath TestsCytochrome P-450 CYP3A InhibitorsHep G2 CellsHumansMolecular StructureStructure-Activity RelationshipCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsVolatile Organic CompoundsbiotransformationbutanoneCYP3A4mass spectrometryvolatile metabolites

Identifiers

PMID40851492
PMCPMC12479387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.